ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations.
First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study (NCT05396885) assessing treatment with anitocabtagene autoleucel (anito-cel) among patients with relapsed/refractory multiple myeloma.1 According to Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, the novel cellular therapy elicited an overall response rate (ORR) of 96% and a stringent complete response or CR rate of 74% among the evaluable patients. She also discussed how anito-cel’s unique mechanism of action may show efficiency compared with other cellular therapy products while reducing the risk of cytokine release syndrome and other delayed toxicities.
Next, Manali Kamdar, MD, spoke about data from a long-term follow-up phase 2/3 study (NCT03435796) based on the phase 3 TRANSFORM trial (NCT03575351) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) vs standard-of-care therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL).2 Long-term follow-up showed that liso-cel continued to elicit improvements in progression-free survival and overall survival across this population. Kamdar, the clinical director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, touched upon the patient subpopulations who are most suitable to receive liso-cel while emphasizing the agent’s curative potential in the second-line setting.
Finally, Wei Ying Jen, BM BCh, MA, MMed, MRCP, FRCPath, detailed results from the phase 1/2 SAVE trial (NCT05360160), which showed responses with an all-oral combination of revumenib (Revuforj), decitabine/cedazuridine (Inqovi), and venetoclax (Venclexta) for patients with newly diagnosed acute myeloid leukemia.3 Jen, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, noted how an all-oral regimen may offer an “advantage” compared with standard intensive chemotherapy, which requires patients to travel to the hospital to undergo an infusion.
References
- Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: updated results from iMMagine-1. Blood. 2025;146(suppl 1):256. doi:10.1182/blood-2025-256
- Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. 2025;146(suppl 1):3710. doi.10.1182/blood-2025-3710
- Jen WY, DiNardo CD, Short NJ, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(suppl 1):47. doi:10.1182/blood-2025-47
Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
December 13th 2025“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.
